Whether a coronavirus vaccine involves a live virus or a carrier organism, it will probably require more than one injection. But that’s not a bad thing.
Academic rigour, journalistic flair
Articles on SARS-CoV-2
Displaying 381 - 400 of 587 articles
Research shows that children can become infected with the coronavirus and spread it to others. Though rare, some kids do become severely ill and a few have died from COVID-19.
Many people are reporting persistent symptoms like headaches and shortness of breath after two months or more since being infected.
Ideally everyone could get tested frequently for the coronavirus. No state is close to achieving this, but some are doing better than others. What are the challenges in meeting demand for testing?
A new study not only shows that the malarial drug chloroquine doesn’t block SARS-CoV-2 from infecting lung cells, but also explains why.
Healthcare workers bear the extraordinary practical and psychological challenges of working daily with the threat of infection and for many months.
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
A team of researchers from Indiana University performed random testing for SARS-CoV-2 across the state. The results offer some of the most accurate data to date about important aspects of the virus.
On a family camping trip over the Australia Day long weekend, I sat in a tent with my laptop, designing New South Wales’ first genomic sequencing test for COVID-19.
The experimental vaccine stimulates the creation of antibodies. Now we need to show that these effectively protect us from the coronavirus.
COVID-19 antibody tests can’t replace the use of PCR tests in people showing symptoms. But they can help test people who may be infected and asymptomatic.
Scientists have developed and tested a new anti-clotting drug in mice that shows promise for treating heart attacks and stroke. It may also prove useful for COVID-19.
The percentage of people who die from a coronavirus infection is an important number for public health experts to know. Recent estimates now put it at 0.65%, far lower than initially thought.
As the pandemic drags on, uncertainty and fears about health and safety mix with confusion and challenges tied to re-opening society. You need flexibility when picking your coping strategies.
My international research project was put on hold – so I volunteered to become a COVID-19 tester. Here’s what I learned.
Vaccine development usually spans a number of decades. This is because there’s a need to understand the mechanisms of protection against the pathogen, and to minimise adverse reactions.
As if the symptoms of COVID-19 were not disturbing enough, physicians have noted a rare neurological condition that emerges during some severe cases of this viral infection.
239 scientists have penned an open letter to the WHO arguing COVID-19 likely spreads through the air. But what is airborne transmission, and how strong is the evidence COVID-19 spreads this way?
There’s no scientific definition for a wave of disease – and no evidence that the original onslaught of coronavirus in the US has receded much at all.
Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science’s normal process of self-correction.
Top contributors
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor, Epidemiology, Deakin University
-
Research Leader in Virology and Infectious Disease, Griffith University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor, Nursing, School of Nursing and Midwifery, Griffith University
-
Postdoctoral Fellow in Virology, University of Colorado Boulder
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Scientific Officer, University of Leeds
-
Lecturer in Virology, Queen's University Belfast
-
Professor of Molecular, Cellular and Developmental Biology, University of Colorado Boulder
-
Postdoctoral Fellow in Virology and Immunology, University of Colorado Boulder
